Maxcyte, Inc. (MXCT) Financial Statements
Industry: Commercial Physical & Biological Research (Services)
In fiscal 2025, Maxcyte reported revenue of $33.0M, down 14.5% from $38.6M the year before. Net income was -$44.6M (a -135.1% net margin), or -$0.42 per diluted share. Gross margin was 81.2% and operating margin was -157.1%. Operating activities generated -$34.4M of cash, leaving -$36.2M of free cash flow. At fiscal year end, Maxcyte held $202.5M in total assets against $31.0M in total liabilities, including $20.1M of cash and equivalents.
Open the full interactive Maxcyte financials → Quarterly statements, key ratios, valuation history and price charts.
Maxcyte Key Stats
| Share Price | $0.96 |
|---|---|
| Market Cap | $103.0M |
| Revenue YoY Growth | -14.5% |
| 52-Week Range | $0.68 – $1.83 |
| Shares Outstanding | 106.8 million (basic, 2026 Q2) |
Maxcyte Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $33.9M | $44.3M | $41.3M | $38.6M | $33.0M |
| Cost of Goods Sold | $3.6M | $5.1M | $4.7M | $7.1M | $6.2M |
| Gross Profit | $30.2M | $39.2M | $36.5M | $31.5M | $26.8M |
| Operating Income | -$18.2M | -$27.4M | -$48.3M | -$51.2M | -$51.9M |
| Pre-Tax Income | -$19.1M | -$23.6M | -$37.9M | -$41.1M | -$44.6M |
| Income Tax | $0 | — | — | — | — |
| Net Income | -$19.1M | -$23.6M | -$37.9M | -$41.1M | -$44.6M |
| Diluted EPS | -$0.21 | -$0.23 | -$0.37 | -$0.39 | -$0.42 |
Maxcyte Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $6.8M | $7.3M | $9.7M | $7.3M |
| Net Income | -$12.4M | -$9.6M | -$4.8M | -$8.9M |
| Diluted EPS | -$0.12 | -$0.09 | -$0.04 | -$0.08 |
Maxcyte Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash & Equivalents | $47.8M | $11.1M | $46.5M | $27.9M | $20.1M |
| Current Assets | $270.4M | $252.3M | $190.2M | $171.7M | $118.4M |
| Total Assets | $284.1M | $286.7M | $268.3M | $239.5M | $202.5M |
| Current Liabilities | $15.6M | $15.4M | $17.9M | $15.8M | $14.3M |
| Total Liabilities | $21.2M | $32.7M | $36.1M | $33.2M | $31.0M |
| Shareholders' Equity | $262.9M | $254.0M | $232.2M | $206.3M | $171.5M |
Maxcyte Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash From Operations | -$10.7M | -$14.8M | -$21.7M | -$27.6M | -$34.4M |
| Cash From Investing | -$195.0M | -$24.8M | $55.0M | $6.9M | $25.9M |
| Cash From Financing | $234.7M | $2.9M | $2.1M | $2.1M | $656,000 |
| Free Cash Flow | -$14.5M | -$33.3M | -$25.4M | -$29.3M | -$36.2M |
Figures from Maxcyte's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Maxcyte financials page for every line item.
Maxcyte Company Profile
| Ticker | MXCT |
|---|---|
| Exchange | Nasdaq |
| Industry | Commercial Physical & Biological Research (Services) |
| Headquarters | Rockville, Maryland |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company, emerging growth company |
| SEC CIK | 0001287098 |
Frequently Asked Questions
What was Maxcyte's revenue in fiscal 2025?
Maxcyte (MXCT) reported revenue of $33.0M for fiscal 2025.
What is Maxcyte's annual revenue history?
Maxcyte's annual revenue by fiscal year: 2021: $33.9M; 2022: $44.3M; 2023: $41.3M; 2024: $38.6M; 2025: $33.0M.
What was Maxcyte's net income in fiscal 2025?
Maxcyte reported net income of -$44.6M for fiscal 2025.
What was Maxcyte's earnings per share (EPS) in fiscal 2025?
Maxcyte's diluted EPS was -$0.42 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Maxcyte generate in fiscal 2025?
Maxcyte generated -$36.2M of free cash flow in fiscal 2025.
What was Maxcyte's revenue last quarter?
In its most recent reported quarter (2026 Q2), Maxcyte reported revenue of $7.3M.
How many shares of Maxcyte are outstanding?
Maxcyte reported a weighted average of 106.8 million basic shares outstanding in 2026 Q2.
What is Maxcyte's market cap?
Based on its latest closing price, Maxcyte (MXCT) has a market capitalization of about $103.0M.
When does Maxcyte's fiscal year end?
Maxcyte's fiscal year end, as registered with the SEC, is December 31.
Where is Maxcyte headquartered?
Maxcyte lists its business address in Rockville, Maryland in its SEC filings.
Maxcyte Competitors & Similar Companies
See all 12 Commercial Physical & Biological Research (Services) companies →